Molixan (glutathione/inosine) / Cellectar - LARVOL DELTA

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (clinicaltrials.gov) - P2 | N=22 | Completed | Sponsor: Cellectar Biosciences, Inc. | N=40 ➔ 22

Enrollment change • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca Responses in Rat Peritoneal Macrophages. (PubMed, Cell tissue biol) - "To elucidate the involvement of sigma-1 receptors in the processes of Ca signaling in macrophages we studied the effect of sigma-1 receptor ligands, phenothiazine neuroleptics chlorpromazine and trifluoperazine, on Ca responses induced by inhibitors of endoplasmic Ca-ATPases thapsigargin and cyclopiazonic acid, as well as by disulfide-containing immunomodulators Glutoxim and Molixan in rat peritoneal macrophages. The data obtained indicate the participation of sigma-1 receptors in a complex signaling cascade caused by Glutoxim or Molixan and leading to an increase in intracellular Ca concentration in macrophages. The results also indicate the involvement of sigma-1 receptors in the regulation of store-dependent Caentry in macrophages."

Journal • Preclinical • Immune Modulation • Inflammation

Clinical Study in the Treatment of Patients With COVID-19 (clinicaltrials.gov) - P3; N=330; Recruiting; Sponsor: Pharma VAM; Trial completion date: Oct 2021 ➔ Sep 2022; Trial primary completion date: Aug 2021 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Myelodysplastic Syndrome • Novel Coronavirus Disease • Respiratory Diseases • CRP

Clinical Study in the Treatment of Patients With COVID-19 (clinicaltrials.gov) - P3; N=330; Recruiting; Sponsor: Pharma VAM; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Myelodysplastic Syndrome • Novel Coronavirus Disease • Respiratory Diseases • CRP

Clinical Study in the Treatment of Patients With COVID-19 (clinicaltrials.gov) - P3; N=330; Not yet recruiting; Sponsor: Pharma VAM

Clinical • New P3 trial • Infectious Disease • Myelodysplastic Syndrome • Novel Coronavirus Disease • Respiratory Diseases • CRP

Neuroleptic Chlorpromazine Modulates Ca Responses in Macrophages. (PubMed, Dokl Biochem Biophys) - "Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor antagonist neuroleptic chlorpromazine significantly inhibits glutoxim- and molixan-induced Ca responses and Ca responses induced by endoplasmic reticulum Са-ATPase inhibitors thapsigargin and cyclopiazonic acid in rat peritoneal macrophages. The results suggest the involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca concentration increase and in the regulation of store-dependent Ca entry in macrophages."

Journal